C. STOCKHOLDERS EQUITY (Details) - USD ($)	3 Months Ended				6 Months Ended
	Mar. 31, 2019	Dec. 31, 2018	Mar. 31, 2018	Dec. 31, 2017	Mar. 31, 2019	Mar. 31, 2018
Common Stock
Beginning balance	$ 278,435	$ 280,346	$ 132,581	$ 119,031	$ 280,346	$ 119,031
Beginning balance, shares	27,843,327	28,034,487	13,258,051	11,903,133	28,034,487	11,903,133
Sale of common stock			$ 25,011	$ 12,895
Sale of common stock, shares			2,501,145	1,289,478
Warrant exercises	$ 15,239	$ 2,987
Warrant exercises, shares	1,523,933	298,682
401(k) contributions paid in common stock	$ 104	$ 123	$ 259	$ 190
401(k) contributions paid in common stock, shares	10,419	12,279	25,901	18,984
Stock issued to nonemployees for service	$ 774	$ 628	$ 1,241	$ 137
Stock issued to nonemployees for service, shares	77,449	62,784	124,082	13,705
Conversion of notes payable and interest to common stock			$ 554
Conversion of notes payable and interest to common stock, shares			55,373
Shares issued (returned) for settlement of clinical research costs	$ 5,000	$ (5,649)	$ 6,600
Shares issued (returned) for settlement of clinical research costs, shares	500,000	(564,905)	660,000
Equity based compensation - employees	$ (35)
Equity based compensation - employees, shares	(3,500)
Ending balance	$ 299,517	$ 278,435	$ 166,246	$ 132,581	$ 299,517	$ 166,246
Ending balance, shares	29,951,628	27,843,327	16,624,552	13,258,051	29,951,628	16,624,552
Additional Paid-In Capital
Beginning balance	$ 332,775,129	$ 331,312,184	$ 300,975,618	$ 296,298,401	$ 331,312,184	$ 296,298,401
Sale of common stock			4,652,130	2,437,105
Warrant exercises	2,640,395	646,766
401(k) contributions paid in common stock	36,779	35,118	36,261	35,690
Stock issued to nonemployees for service	224,855	201,752	227,254	25,270
Conversion of notes payable and interest to common stock			108,746
Shares issued (returned) for settlement of clinical research costs	1,285,000	5,649	1,240,800
Equity based compensation - employees	530,865	573,660		1,448,098
Stock issuance cost	(43,625)		(94,773)
Ending balance	337,449,398	332,775,129	307,425,853	300,975,618	337,449,398	307,425,853
Accumulated Deficit
Beginning balance	(330,345,712)	(331,591,614)	(305,942,239)	(299,754,409)	(331,591,614)	(299,754,409)
Net income (loss)	(6,447,681)	1,245,902	(4,708,135)	(6,187,830)
Ending balance	(336,793,393)	(330,345,712)	(310,650,374)	(305,942,239)	(336,793,393)	(310,650,374)
Beginning balance	2,707,852	916	(4,834,040)	(3,336,977)	916	(3,336,977)
Sale of common stock			4,667,141	2,450,000
Warrant exercises	2,655,634	649,753
401(k) contributions paid in common stock	36,883	35,241	36,520	35,880	72,124	72,400
Stock issued to nonemployees for service	225,629	202,380	228,495	25,407
Conversion of notes payable and interest to common stock			109,300
Shares issued (returned) for settlement of clinical research costs	1,290,000	0	1,247,400
Equity based compensation - employees	530,830	573,660		1,448,098
Stock issuance cost	(43,625)		(94,773)
Net income (loss)	(6,447,681)	1,245,902	(4,708,135)	(6,187,830)	(5,201,779)	(10,895,965)
Ending balance	$ 955,522	$ 2,707,852	$ (3,058,275)	$ (4,834,040)	$ 955,522	$ (3,058,275)